Skin Lesions in a Daclizumab-Treated Patient with Multiple Sclerosis
March 2019
in “
Journal of Interdisciplinary Medicine
”
Studysummary This case report details a middle-aged man with multiple sclerosis who developed difficult-to-evaluate skin reactions after daclizumab treatment, noting only slight improvement with additional therapies.
Our plain-language summary. Not medical advice or a treatment recommendation. Consult a qualified healthcare professional before changing treatment. Full disclaimer
In 2019, a case was presented of a middle-aged man with multiple sclerosis who was treated with Daclizumab, a humanized monoclonal antibody against the D-subunit (CD25) of the high-affinity interleukin (IL)–2 receptor. The patient developed skin reactions that were difficult to evaluate. A biopsy from the plantar area showed hyperkeratosis and acanthosis, but no parakeratosis, and a discrete inflammatory infiltrate was noticed around vessels in the dermis. Treatment with fluconazole 50 mg/day for 10 days, moisturizers, and grade I topical steroids led to slight improvement. The treatment with daclizumab was not discontinued. The study concluded that the clinical efficacy and side effects of daclizumab needed further reporting and confirmation in clinical practice in the following years.
